Product Approval
← 실적 발표
01
02
03
04 05 06
톤
AI
A1 A2 A3 A4 A5
MRNA
FY2026 Q1
개선
Moderna, Inc. 실적 발표
Buzzberg 분석
First flu-COVID combo vaccine approved in EU, fourth product approved.
Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery.
Buzzberg 분석 First flu-COVID combo vaccine approved in EU, fourth product approved. Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery. 전체 분석 보기분석 접기
Moderna reported a strong Q1 with higher-than-expected revenue driven by UK partnership deliveries, reiterating its up to 10% growth guidance for 2026. Q1 revenues of $400M up significantly y/y, driven by the UK spring campaign delivery.
- EU approval of the first flu+COVID combination vaccine (mCombriax) and MnexPak approvals in the EU are key regulatory wins, positioning for 2027 launches.
- Completed a $950M settlement with Arbutus/Genebon; a potential $1.3B further liability is not reserved.
- Initiated a new Phase III lung cancer study in stage 1 disease, potentially expanding INT to a wider patient population.
매출$0.389B-43% 전분기 대비
주당순이익(EPS)$-3.40보고값
잉여현금흐름$-0.692B보고값
자본지출$0.062B보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
New Phase 3 trial in stage one NSCLC initiated.
Demand
UK spring and fall deliveries expected; international revenue strong.
핵심 내용 3개 더 보기
Pipeline
Norovirus Phase 3 fully enrolled, data expected in 2026.
Pipeline
PA program pivotal data expected later this year; MMA deferred.
Costs
R&D costs down 24% YoY, adjusted cash costs down 26%.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $0.389B | -43% 전분기 대비 |
| 주당순이익(EPS) | $-3.40 | 보고값 |
| 잉여현금흐름 | $-0.692B | 보고값 |
| 자본지출 | $0.062B | 보고값 |
| 순이익 | $-1.343B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | $0.2B–$0.3B | $0.25B | 유지 |
| 매출 | FY2026 | $0B | $0B | 유지 |
| 매출 | FY2026 | $4.5B–$5B | $4.75B | 제시 |
| 매출 | FY2026 Q2 | $0.05B–$0.1B | $0.075B | 제시 |
| 매출 | FY2026 Q1 | $0.4B | $0.4B | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in execution, highlighting strong Q1 performance, reiterating guidance, and emphasizing multiple upcoming catalysts across the pipeline.
경영진의 AI 분석
Management highlighted ongoing investment in AI with cross-enterprise projects to reinvent work and drive personal productivity, positioning AI as a tool to accelerate discovery and expand mRNA into new modalities.
아래에 언급된 기업 4개 모두 표시
기업발표 이후 수익률
파트너
파트너
Stephen Hogue
The initiation of the INT Phase III in stage 1 lung cancer as a monotherapy is a significant expansion of the addressable market and a potentially pivotal trial. — Success could open a huge market segment where treatment is surgery and watchful waiting, and also support a monotherapy profile for INT.
근거
“We and our partner, Merck, have been really excited by the clinical data that we've seen within TIS4N to date”
파트너
Stéphane Boncel
CEPI's support is funding Moderna's pandemic flu program, now in Phase III, a non-commercial partnership.
근거
“we support from CEPI, our pandemic flu program, mRNA-1018, has now initiated its phase three study”
공급망
공급망
Jamie Mock
A settlement payment shared with Arbutus will be a cash inflow for Geneosoma, but the exact split is not disclosed.
근거
“we entered into a settlement agreement with Arbutus and Genobon, resolving all litigation with them worldwide.”
외부 신호
공급망 알파 · 5발표 이후 수익률
The initial flu+COVID combo vaccine (mCombriax) approval in the EU creates manufacturing complexity for Moderna, but they expect no revenue in 2026, indicating launch is back-end loaded to 2027.
근거
“we do not expect revenues in the year of approval for these vaccines. And so, 1083 or M-combriax or flu in the United States, none of those are in our guidance”
A $950M settlement payment to Arbutus/Genebon is due in Q3 2026, but Moderna has not reserved the potential $1.3B Section 1498 liability, creating a binary cash risk event in 2027-2028.
근거
“If, however, the Federal Circuit affirms liability under Section 1498, Moderna has agreed to make an additional payment of up to $1.3 billion.”
mRNA-1010 flu vaccine receives PDUFA date of August 5, 2026 in the US; FDA review is progressing 'normal course' with no commentary on new CBER leadership affecting the review.
근거
“we are awaiting further guidance from the FDA on the next steps for resuming filing in the United States.”
The initiation of the INT Phase III in stage 1 lung cancer as a monotherapy is a significant expansion of the addressable market and a potentially pivotal trial.
근거
“the right approach there was to go into a phase three, potentially pivotal study.”
The MMA program has been deferred until after PA readout, indicating management is prioritizing the more de-risked PA program for capital allocation.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 4개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.